Promega Pd-1Pd-L1 Cell

PD-1/PD-L1 inhibitor 1
B6172-25 25 mg
EUR 278.4
Description: Apoptosis|PD-1/PD-L1 interaction

Human IgG antibody Laboratories manufactures the promega pd-1/pd-l1 cell reagents distributed by Genprice. The Promega Pd-1/Pd-L1 Cell reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Promega. Other Promega products are available in stock. Specificity: Promega Category: Pd-1/Pd-L1 Group: Cell

PD-1/PD-L1 inhibitor 2
5 mg
EUR 84
Description: Apoptosis|PD-1/PD-L1 interaction#Apoptosis

PD-1/PD-L1 Inhibitor 3
1 mg
EUR 248.8
Description: Apoptosis|PD-1/PD-L1 interaction

PD-1/PD-L1 Inhibitor 3
5 mg
EUR 837.6
Description: Apoptosis|PD-1/PD-L1 interaction

PD-1/PD-L1 Inhibitor 2
each
EUR 679.2

PD-1/PD-L1 Inhibitor 2
each
EUR 242.4

PD-1/PD-L1-IN-31
Get quote Ask for price
Description: PD-1/PD-L1-IN-31 is a PD-1/PD-L1 inhibitor (IC50=2.2 nM). PD-1/PD-L1-IN-31 promotes secretion of the IFN-γ, and induces immune activity of peripheral blood mononuclear cells (PBMCs) to inhibits tumor cells[1].

PD-1/PD-L1-IN-29
1 mg
EUR 919.93
Description: PD-1/PD-L1-IN-29 (S4-1) is a potent PD-1/PD-L1 inhibitor with an IC50 value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity[1].

Cell information

PD-1/PD-L1 Inhibitor 3
B6191-1 1 mg
EUR 248.8
Description: Apoptosis|PD-1/PD-L1 interaction

PD-1/PD-L1 Inhibitor 3
B6191-5 5 mg
EUR 837.6
Description: Apoptosis|PD-1/PD-L1 interaction

PD-1/PD-L1 Inhibitor 2
B1050-25 each
EUR 679.2

PD-1/PD-L1 Inhibitor 2
B1050-5 each
EUR 242.4

PD-1/PD-L1-IN-31
HY-149356 Get quote Ask for price
Description: PD-1/PD-L1-IN-31 is a PD-1/PD-L1 inhibitor (IC50=2.2 nM). PD-1/PD-L1-IN-31 promotes secretion of the IFN-γ, and induces immune activity of peripheral blood mononuclear cells (PBMCs) to inhibits tumor cells[1].

PD-1/PD-L1-IN-29
HY-152240 1 mg
EUR 919.93
Description: PD-1/PD-L1-IN-29 (S4-1) is a potent PD-1/PD-L1 inhibitor with an IC50 value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity[1].

PD-1/PD-L1-IN 3
HY-103048 Get quote Ask for price
Description: PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases[1].

PD-1/PD-L1-IN-34
HY-154869 Get quote Ask for price
Description: PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) inhibits PD-1/PD-L1 interaction (IC50=0.029 μM), with a selected binding affinity with PD-L1 (KD=0.1554 μM). PD-1/PD-L1-IN-34 inhibits tumor growth by activating the immune microenvironment[1].

PD-1/PD-L1-IN-32
HY-155740 Get quote Ask for price
Description: PD-1/PD-L1-IN-32 (compound A56) is a potent PD-1/PD-L1 inhibitor (IC50=2.4 nM), with anticancer activity. PD-1/PD-L1-IN-32 significantly inhibits tumor growth in hPD-L1 MC38 humanized mouse model, without obvious toxicity against mouse normal ability[1].

PD-1/PD-L1-IN-33
HY-155959 10 mg
EUR 1623.4
Description: PD-1/PD-L1-IN-33 (Compound N11) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC50: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity[1].

PD-1/PD-L1-IN-36
HY-163041 Get quote Ask for price
Description: PD-1/PD-L1-IN-36 (Compound 2k) is a PD-1/PD-L1 complex inhibitor (IC50: 15 nM). PD-1/PD-L1-IN-36 can be used for research of cancer immunotherapy[1].

PD-1/PD-L1-IN 5
HY-129172A Get quote Ask for price
Description: PD-1/PD-L1-IN 5 is a PD-1/PD-L1 protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC50 of ≤100 nM[1].

PD-1/PD-L1-IN 6
HY-130625 Get quote Ask for price
Description: PD-1/PD-L1-IN 6 (compound A13) is a potent PD-1/PD-L1 interaction inhibitor, with an IC50 of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model[1].

PD-1/PD-L1-IN-NP19
HY-131347 10 mg
EUR 1948.08
Description: PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects[1].

PD-1/PD-L1-IN-9
HY-132192 10 mg
EUR 984.86
Description: PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model[1].

PD-1/PD-L1-IN-10
HY-132202 10 mg
EUR 779.23
Description: PD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy[1].

PD-1/PD-L1-IN-13
HY-145239 1 mg
EUR 3517.37
Description: PD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8+ T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse model[1].